- Home
- WLDN vs EWTX Comparison
WLDN vs EWTX Comparison
Compare WLDN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLDN
- EWTX
- Stock Information
- Founded
- WLDN 1964
- EWTX 2017
- Country
- WLDN United States
- EWTX United States
- Employees
- WLDN N/A
- EWTX N/A
- Industry
- WLDN Military/Government/Technical
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- WLDN Consumer Discretionary
- EWTX Health Care
- Exchange
- WLDN Nasdaq
- EWTX Nasdaq
- Market Cap
- WLDN 1.6B
- EWTX 1.6B
- IPO Year
- WLDN 2006
- EWTX 2021
- Fundamental
- Price
- WLDN $94.51
- EWTX $18.28
- Analyst Decision
- WLDN Strong Buy
- EWTX Buy
- Analyst Count
- WLDN 3
- EWTX 10
- Target Price
- WLDN $114.33
- EWTX $37.90
- AVG Volume (30 Days)
- WLDN 230.5K
- EWTX 826.7K
- Earning Date
- WLDN 11-06-2025
- EWTX 11-06-2025
- Dividend Yield
- WLDN N/A
- EWTX N/A
- EPS Growth
- WLDN 94.22
- EWTX N/A
- EPS
- WLDN 2.39
- EWTX N/A
- Revenue
- WLDN $628,172,000.00
- EWTX N/A
- Revenue This Year
- WLDN N/A
- EWTX N/A
- Revenue Next Year
- WLDN $9.00
- EWTX N/A
- P/E Ratio
- WLDN $39.46
- EWTX N/A
- Revenue Growth
- WLDN 13.82
- EWTX N/A
- 52 Week Low
- WLDN $30.43
- EWTX $10.60
- 52 Week High
- WLDN $121.00
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- WLDN 48.03
- EWTX 66.33
- Support Level
- WLDN $90.59
- EWTX $14.68
- Resistance Level
- WLDN $103.79
- EWTX $18.78
- Average True Range (ATR)
- WLDN 4.56
- EWTX 0.95
- MACD
- WLDN -0.09
- EWTX 0.31
- Stochastic Oscillator
- WLDN 32.11
- EWTX 88.96
About WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.